Skip to main content
Fig. 2 | Orphanet Journal of Rare Diseases

Fig. 2

From: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study

Fig. 2

Mean intra-subject change from baseline (95% CI) in patient-reported outcomes, baselinea to end of studyb. Note Mean and 95% CI values can be found in Additional file 1. aBaseline was visit 1 (week 1) of the open-label study. bFinal visit (week 53 or extension period week 88 for subjects who participated in the extension period). C1-INH(SC) subcutaneous C1-inhibitor, CI confidence interval, EQ-5D European Quality of Life-5 Dimensions Questionnaire, HADS Hospital Anxiety and Depression Scale, TSQM Treatment Satisfaction Questionnaire for Medication, WPAI Work Productivity and Activity Impairment Questionnaire, CI confidence interval

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172